Cancer Therapy-induced Dermatotoxicity as a Window to Understanding Skin Immunity.
Depigmentation
Epidermis
Macrophage
Nerve
Pruritis
Rash
T cell
Journal
Hematology/oncology clinics of North America
ISSN: 1558-1977
Titre abrégé: Hematol Oncol Clin North Am
Pays: United States
ID NLM: 8709473
Informations de publication
Date de publication:
11 Jun 2024
11 Jun 2024
Historique:
medline:
13
6
2024
pubmed:
13
6
2024
entrez:
12
6
2024
Statut:
aheadofprint
Résumé
Pruritus, rash, and various other forms of dermatotoxicity are the most frequent adverse events among patients with cancer receiving targeted molecular therapy and immunotherapy. Immune checkpoint inhibitors, macrophage-targeting agents, and epidermal growth factor receptor/MEK inhibitors not only exert antitumor effects but also interfere with molecular pathways essential for skin immune homeostasis. Studying cancer therapy-induced dermatotoxicity helps us identify molecular mechanisms governing skin immunity and deepen our understanding of human biology. This review summarizes new mechanistic insights emerging from the analysis of cutaneous adverse events and discusses knowledge gaps that remain to be closed by future research.
Identifiants
pubmed: 38866636
pii: S0889-8588(24)00051-0
doi: 10.1016/j.hoc.2024.05.002
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure J.L. Flesher is supported by NIH, United States T32AR007098 (Dermatology Training Grant). J.M. Park is supported by NIH R01AI177414, has a consulting role with Chong Kun Dang Pharmaceutical, and has received research funding from Pfizer, United States and Evommune.